The CLL Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The CLL Channel on VJHemOnc is supported by BeiGene. This supporter has no influence over the production of the content.

Latest Videos Genomic Testing & Clinical Decision Making Conferences Topics iwCAR-T 2023 Podcasts Features Expert Editorial Board

Welcome to The Chronic Lymphocytic Leukemia (CLL) Channel

The CLL Channel delivers exciting and topical research in CLL via video interviews, podcasts, roundtable discussions and more. Reporting from key international congresses with world-leading experts, VJHemOnc provides hot topics in CLL such as measurable residual disease (MRD) monitoring, prognostic biomarkers, CAR-T and updates on the use of BTK and BCL-2 inhibitors.

Conferences

BSH 2023
Tandem Meetings 2023
CAR-T Meeting 2023
ASH 2022
ERIC 2022
SOHO 2022
1:52
Novel options for patients with CLL who relapse after treatment with BTK inhibitors and venetoclax
Dima El-Sharkawi • 24 Apr 2023
1:48
The importance of evaluating qualitative outcomes of patients with CLL on targeted therapy
Dima El-Sharkawi • 24 Apr 2023
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023
1:06
Managing cardiac toxicities associated with BTK inhibitors and selecting between these agents
Talha Munir • 24 Apr 2023
View All Videos
1:28
Phase I study of pevonedistat and ibrutinib in R/R B-NHL
Swetha Kambhampati • 23 Feb 2023
3:12
Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Niranjan Shah • 15 Feb 2023
View All Videos
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
1:11
Challenges that have been faced with developing CAR-T products for CLL and future outlooks
Marco Ruella • 9 Feb 2023
1:29
Combining ibrutinib with CAR-T cells: a promising therapeutic strategy in CLL
Marco Ruella • 9 Feb 2023
View All Videos
0:48
The current role of MRD in CLL and future outlooks
Talha Munir • 12 Dec 2022
1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
0:59
The impact of age and comorbidities on the outcomes of patients with CLL treated with BTK inhibitors
Barbara Eichhorst • 11 Dec 2022
View All Videos
1:54
Preventing severe COVID-19 infection in patients with CLL
Yair Herishanu • 7 Oct 2022
2:31
The role of chemoimmunotherapy in the era of targeted therapies for CLL
Lukas Smolej • 7 Oct 2022
1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
2:17
Overcoming resistance to CAR-T therapy in CLL with ibrutinib & venetoclax
Marco Ruella • 7 Oct 2022
View All Videos
1:07
The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda • 28 Sep 2022
2:55
Clinical outcomes of patients with CLL receiving long-term ibrutinib in the RESONATE-2 study
Thomas Kipps • 30 Sep 2022
4:07
Overcoming the challenge of resistance to targeted therapies in CLL
Thomas Kipps • 30 Sep 2022
2:23
The importance of genomic testing in CLL in the era of novel therapies
Nitin Jain • 29 Sep 2022
View All Videos

Topics

MRD
CAR-T & Cellular Therapy
Supportive Care
Transplant
Immuno-Oncology
Disease Biology
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023
0:48
The current role of MRD in CLL and future outlooks
Talha Munir • 12 Dec 2022
1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
View All Videos
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
3:12
Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Niranjan Shah • 15 Feb 2023
1:11
Challenges that have been faced with developing CAR-T products for CLL and future outlooks
Marco Ruella • 9 Feb 2023
View All Videos
3:41
Supportive care for infectious complications in CLL
Clare Sun • 29 Sep 2022
2:29
Treating hypertension in patients receiving BTK inhibitors
Mazyar Shadman • 10 Jun 2022
5:02
Understanding patient perspectives in CLL treatment
Brian Koffman • 9 Sep 2021
2:52
Current challenges in CLL treatment
Brian Koffman • 9 Sep 2021
View All Videos
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
1:03
Genomic tests available to patients with CLL at tertiary hospitals
Lukas Smolej • 7 Oct 2022
0:55
Acalabrutinib in patients with CLL and MCL undergoing alloSCT
Wojciech Jurczak • 11 Jun 2022
1:25
Where are we with CAR-T in CLL?
John Gribben • 9 Jun 2022
View All Videos
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023
1:13
Factors to consider when selecting between continuous and fixed-duration therapy in CLL
Talha Munir • 24 Apr 2023
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
View All Videos
3:20
Overcoming venetoclax resistance in myeloid malignancies with selective inhibition of MCL1
Michael Savona • 5 May 2023
3:28
Genomic factors influencing patient response to venetoclax-based regimens: analysis from CLL13/GAIA
Barbara Eichhorst • 11 Dec 2022
3:25
Delivering genomic testing results to patients with CLL
Kerry Rogers • 12 Dec 2022
1:48
Characterizing the development of MDS in patients with CLL in the era of targeted therapies
Adam Kittai • 10 Dec 2022
View All Videos

The CLL Channel on VJHemOnc is supported by BeiGene.

This supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The CLL Channel, please contact us

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals